Rastislav Bahleda

Rastislav Bahleda

UNVERIFIED PROFILE

Are you Rastislav Bahleda?   Register this Author

Register author
Rastislav Bahleda

Rastislav Bahleda

Publications by authors named "Rastislav Bahleda"

Are you Rastislav Bahleda?   Register this Author

29Publications

1203Reads

27Profile Views

Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.

Oral Oncol 2019 Apr 14;91:129-131. Epub 2019 Feb 14.

Department of Head and Neck Cancer, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2019.02.008DOI Listing
April 2019

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 11 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.011DOI Listing
November 2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Br J Cancer 2018 02 16;118(3):344-352. Epub 2018 Jan 16.

Department of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse 31100, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808039PMC
February 2018

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Invest New Drugs 2017 02 25;35(1):79-86. Epub 2016 Oct 25.

Clinical Pharmacology, Henri Mondor Teaching Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Assistance Publique - Hôpitaux de Paris, 94000, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0402-3DOI Listing
February 2017

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J Clin Oncol 2015 Oct 31;33(30):3401-8. Epub 2015 Aug 31.

Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal; Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain; Rastislav Bahleda, Anas Gazzah, and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif; Antoine Italiano, Institut Bergonié, Bordeaux, France; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Bob Zhong, Suso J. Platero, Moitreyee Chatterjee-Kishore, Vijay Peddareddigari, and Feng R. Luo, Janssen Research and Development, Raritan, NJ; and Johan W. Smit and Kim Stuyckens, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7341DOI Listing
October 2015

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 6;32(6):1188-96. Epub 2014 Jun 6.

Drug Development Department (DITEP), University Paris Sud, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0119-0DOI Listing
December 2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

J Clin Oncol 2014 Jan 9;32(2):68-75. Epub 2013 Dec 9.

Leena Gandhi, Sara M. Tolaney, James M. Cleary, and Geoffrey I. Shapiro, Dana-Farber Cancer Institute; Eunice L. Kwak, Massachusetts General Hospital; Shuchi S. Pandya, Beth Israel Deaconess Medical Center, Boston; Anna Berkenblit and Mizue Krygowski, Aveo Pharmaceuticals; Revathi Ananthakrishnan and Kathleen W. Turnbull, Inventiv Health, Cambridge, MA; Rastislav Bahleda, Antoine Hollebecque, and Jean-Charles Soria, Insitut Gussav Roussy, Villejuif, France; Richat Abbas and Yali Liang, Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.47.2787
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.2787DOI Listing
January 2014

Targeted therapy-induced radiation recall.

Eur J Cancer 2013 May 8;49(7):1662-8. Epub 2013 Jan 8.

Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.12.009DOI Listing
May 2013

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Onco Targets Ther 2013 20;6:95-7. Epub 2013 Feb 20.

SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S38520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581357PMC
March 2013

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Invest New Drugs 2010 Dec 16;28(6):884-6. Epub 2009 Sep 16.

Department of Otolaryngology Head & Neck Surgery, Institut Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-009-9314-9
Publisher Site
http://dx.doi.org/10.1007/s10637-009-9314-9DOI Listing
December 2010

Reversible cardiogenic shock following 5-fluorouracil infusion.

Invest New Drugs 2010 Aug 5;28(4):531-3. Epub 2009 Jun 5.

Phase I unit (SITEP), Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9271-3DOI Listing
August 2010

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Invest New Drugs 2010 Jun 25;28(3):350-2. Epub 2009 Apr 25.

Département de Médecine, Service des Innovations Thérapeutiques Précoces, Institut Gustave Roussy, Université Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-009-9252-6
Publisher Site
http://dx.doi.org/10.1007/s10637-009-9252-6DOI Listing
June 2010

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Invest New Drugs 2010 Feb 3;28(1):102-5. Epub 2009 Apr 3.

Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-009-9247-3
Publisher Site
http://dx.doi.org/10.1007/s10637-009-9247-3DOI Listing
February 2010